Pharmacology of novel nicotinic analogs

Drug Development Research

Volumn 38, Issue 3-4, 1996, Pages 177-187

  Imad Damaj, M ^a   Glassco, William ^a   Dukat, Malgorzata ^a   May, Everett L ^a   Glennon, Richard A ^a   Martin, Billv R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIBATIDINE; MECAMYLAMINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG DISCRIMINATION; DRUG SYNTHESIS; ENANTIOMER; MALE; MOUSE; NONHUMAN; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030459686     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199607/08)38:3/4<177::AID-DDR6>3.0.CO;2-J     Document Type: Article

References (27)

1. Aceto MD, Martin BR, Uwaydah IM, May EL, Harris LS, Izazola-Conde C, Dewey WL, Vincek WC (1979): Optically pure (+)-nicotine from (±)-nicotine and biological comparisons with (-)-nicotine. J Med Chem 22:174-177.
2. Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz J, Hugues ML, Cadman ED, Adams F, Garvey DS, Wasicak JT, Williams M (1994): (S)-3-Methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT-418): A novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vitro characterization. J Pharmacol Exp Ther 270:310-318.
3. Aubert I, Araujo DM, Cecyre D, Robitaille Y, Gauthier S, Quirion R (1992): Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J Neurochem 58:529-541.
4. Badio B, Daly J (1994): Epibatidine, a potent analgetic and nicotinic agonist. Mol Pharmacol 45:563-569.
5. Court JA, Piggott MA, Perry EK, Barlow RB, Perry RH (1992): Age associated decline in high affinity nicotine binding in human brain frontal cortex does not correlate with the changes in choline acetyltransferase activity. Neurosci Res Comm 10:125-133.
6. Damaj MI, Creasy KR, Grove AD, Rosecrans JA, Martin BR (1994a): Pharmacological effects of epibatidine optical enantiomers. Brain Res 664:34-40.
7. Damaj MI, Tucker S, Aceto M, Martin BR (1994b): Analgesic activity of epibatidine and its enantiomers in a chemical model of pain in mice. Med Chem Res 4:483-492.
8. D'Amour FE, Smith DL (1941): A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74-79.
9. 125I-α-bungarotoxin receptor subtypes. Mol Pharmacol 47:164-171.
10. Dewey WL, Harris LS, Howes JS, Nuite JA (1970): The effect of various neurohormonal modulations on the activity of morphine and the narcotic antagonists in taik-flick and phenylquinone test. J Pharmacol Exp Ther 175:435-442.
11. Dukat M, Damaj MI, Glassco W, Dumas D, May EL, Martin BR, Glennon RA (1993): Epibatidine: A very high affinity nicotine-receptor ligand. Med Chem Res 4:131-139.
12. Dukat M, Damaj MI, Glassco W, Dumas D, May EL, Martin BR, Glennon RA (1995): Epibatidine. In Clarke PBS, Quik M, Adlkofer F, Thurau K (eds): Effects of Nicotine on Biological Systems II. Basel: Birkhauser, pp 371-378.
13. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ (1992): A subtype of nicotinic cholinergic receptor in the rat brain is composed of alpha-4 and beta-2 subunits and is upregulated by chronic nicotine treatment. Mol Pharmacol 41:31-37.
14. Glassco W, Suchocki J, George C, Martin B, May E (1993): Synthesis, optical resolution, absolute configuration, and preliminary pharmacology of (+)-abd(-)-cis,2,3,3a,4,5,9b-hexahydro-1-methyl-1h-pyrrolo-[3,2-h] isoquinoline, a structural nanlog of nicotine. J Med Chem 36:3381-3385.
15. Glassco W, May EL, Damaj MI, Martin BR (1994a): In vivo and in vitro activity of some N-substituted (±)-nornicotine analogs. Med Chem Res 4:273-282.
16. Glassco W, May EL, Weaver V, Damaj MI, Rosecrans J, Martin BR (1994b): Pharmacological investigation of N-substituted derivatives of (±)-norisonicotine. Med Chem Res 4:474-482.
17. Glennon RA, Maarouf A, Fahmy S, Martin B, Fan F, Yousif M, Shafik RM, Dukat M (1993): Structure-affinity relationships of simple nicotine analogs. Med Chem Res 2:546-551.
18. Glennon RA, Herndon JL, Dukat M (1994): Epibatidine-aided studies toward definition of a nicotine-receptor pharmacophore. Med Chem Res 4:461-473.
19. Holladay MW, Lebold SA, Lin N-H (1995): Structure-activity relationships of nicotinic acetylcholine receptors agonists as potential treatments for dementia. Drug Dev Res 35:191-213.
20. Martin BR, Onaivi ES, Martin TJ (1989): What is the nature of mecamylamine's antagonism of the central effects of nicotine? Biochem Pharmacol 38:3391-3397.
21. McDonald IA, Cosford N, Vernier J-M (1995): Nicotinic acetylcholine receptors: Molecular biology, chemistry and pharmacology. Ann Rep Med Chem 30:41-50.
22. Rosecrans JA (1989): Nicotine as a discriminative stimulus: A neurobiobehavioral approach to studying central cholinergic mechanisms. J Subst Abuse 1:287-300.
23. Sargent PB (1993): The diversity of neuronal nicotinic acetylcholine receptors. Ann Rev Neurosci 16:403-443.
24. 3H]nicotine binding to mouse brain homogenate. J Pharm Pharmacol 40:793-797.
25. Swanson KL, Aronstam RS, Wonnacott S, Rapoport H, Albuquerque EX (1991): Nicotinic pharmacology of anatoxin analogs. I. Side chain structure-activity relationships at peripheral agonist and noncompetitive antagonist sites. J Pharmacol Exp Ther 259:377-386.
26. Ward J, Cockcroft V, Lunt G, Smillie F, Wonnacott S (1990): Methyllycaconitine: A selective probe for neuronal α-bungarotoxin binding sites. FEBS 270:45-48.
27. Wonnacott S, Jackman S, Swanson KL, Rapoport H, Albuquerque EX (1991): Nicotinic pharmacology of anatoxin analogs. II. Side chain structure-activity relationships at neuronal nicotinic ligand binding sites. J Pharmacol Exp Ther 259:387-391.